Core Viewpoint - The event "Praise for China's Economy - Entrepreneur Night" highlighted the achievements of Qiangnao Technology, a leader in non-invasive brain-computer interface technology, and its impact on improving the lives of disabled individuals [1][8]. Group 1: Company Achievements - Qiangnao Technology, led by CEO Han Bicheng, has become a global leader in non-invasive brain-computer interface technology, breaking foreign monopolies and turning science fiction into reality through ten years of technological innovation [3][10]. - The company has developed advanced products such as intelligent bionic hands and legs, which have restored life capabilities to disabled individuals and provided hope to over a thousand children with autism [3][10]. - The company aims to use cutting-edge technology to help approximately 5 million people in China with limb disabilities regain their ability to work and live independently [4][12]. Group 2: Social Impact - The technology developed by Qiangnao is not just about high-tech solutions but focuses on restoring the lives of individuals who have faced significant challenges due to disabilities [6][13]. - A notable case involved a user who had lost a hand for 27 years, who expressed that the technology allowed him to feel as if he had his hand back after successfully using a bionic prosthetic to grasp a cup [6][13]. - The company is also working on products aimed at addressing sleep issues, highlighting the broader applications of brain-computer interface technology in improving quality of life [7][14].

Core Insights - The Sci-Tech Innovation Board (STAR Market) has achieved significant milestones in its seven years of operation, with over 600 listed companies and a total market capitalization exceeding 10 trillion yuan, raising over 1.1 trillion yuan through IPOs and refinancing [1] - The "Sci-Tech Exchange" initiative aims to address industry development challenges and promote a virtuous cycle of technology, industry, and capital by connecting various stakeholders [1][2] Group 1: STAR Market Achievements - The STAR Market has become a core platform for nurturing new productive forces and promoting technological self-reliance, characterized by high levels of innovation, technology, and capital [1] - The board's reforms have expanded the scope of the fifth set of standards to include cutting-edge fields such as embodied intelligence, chips, large models, brain-computer interfaces, and commercial aerospace [1][5] Group 2: Sci-Tech Exchange Initiative - The "Sci-Tech Exchange" initiative focuses on four core objectives: value discovery, benchmark establishment, resource linking, and ecosystem co-construction [2] - The initiative will conduct in-depth analysis and research on five key cutting-edge fields, ensuring a comprehensive approach to industry chain integrity and technological innovation [5] Group 3: Communication and Impact - The initiative will utilize a multi-format communication strategy, including text, video, live broadcasts, and offline events, to enhance its influence and reach [6] - A comprehensive research campaign will be conducted from February to June 2026, covering major innovation hubs in China to showcase the vitality of the country's sci-tech industry [6]

Core Viewpoint - Zhejiang Qiangnao Technology Co., Ltd. has reportedly submitted a confidential IPO application to the Hong Kong Stock Exchange, with CICC and UBS as joint sponsors, indicating a significant move towards public listing in the rapidly growing brain-computer interface (BCI) sector [1][3]. Company Overview - Founded in February 2015, Qiangnao Technology focuses on the development of non-invasive brain-computer interface technology, with products spanning smart bionics, health, and education [1]. - The company has launched several products, including a smart bionic hand, a brain-machine intelligent sleep device, and an attention training system [1]. Financing History - Qiangnao Technology completed a significant financing round in early January, raising approximately 2 billion RMB, marking it as the second-largest financing in the BCI field globally, after Neuralink [3]. - Since its inception, the company has completed six rounds of financing, including a notable $400 million Series A round in 2019 [3][4]. - The latest financing rounds include a $30 million Pre-B round and a $20 million Series B round in 2025 [4]. Market Trends - The BCI sector is experiencing rapid growth, with 26 financing events in 2025 totaling 1.778 billion RMB, a significant increase from 2024 [5]. - The global BCI market is projected to grow from approximately $2.6 billion in 2024 to $2.9 billion in 2025, with a further increase to $3.3 billion by 2026 [5]. - In China, the BCI market is expected to reach 3.8 billion RMB in 2025, up from 3.2 billion RMB in 2024 [5]. Policy Support - The Chinese government is actively promoting the BCI industry, with policies aimed at fostering innovation and establishing industry clusters by 2027 and 2030 [7]. - The national strategy includes BCI as a key area for economic growth, alongside other advanced technologies [7]. Industry Outlook - Analysts predict that the BCI industry is on the verge of significant growth, driven by commercial advancements and policy support [8]. - The transition from laboratory research to commercialization is expected to accelerate, particularly with the anticipated production scale-up by Neuralink [8].

21世纪经济报道记者闫硕 脑机接口标准化建设传来新消息。 近日，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性 验证方法》等2项医疗器械行业标准制修订项目立项，为采用脑机接口技术的医疗器械高质量发展提供标准支撑。 脑机接口是一种在脑与外部设备之间建立直接的通信渠道。常用于辅助、增强、修复人体的感觉–运动功能或提升人机交互能力，目前在医学 领域应用较为广泛。根据植入条件，脑机接口可分为侵入式、非侵入式和半侵入式三种。 近年来，随着神经信号处理、生物兼容材料、高性能芯片等一系列核心技术接连突破，脑机接口得以快速发展。与此同时，相关支持政策不断 落地，标准化建设成为规范行业发展、保障产品安全有效的关键抓手。 健康通副总裁、首席发展官张畅向21世纪经济报道记者表示，此次2项标准的立项是对工信部等七部门此前发布的《关于推动脑机接口产业创 新发展的实施意见》（简称《实施意见》）中标准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。由此，也 为医疗领域开展相关研究、临床试验等后续"专业步骤"，迈出了有章可循的关键第一步。 强化标 ...

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

鱼羊 发自 凹非寺 量子位 | 公众号 QbitAI 让特斯拉转型成「机器人」公司，马斯克来真的了： 在最新财报电话会议上，马斯克宣布，特斯拉将在2026年第二季度 停产豪华车型Model S和Model X 。 现在是时候让Model S和Model X体面地退出舞台了，因为我们正在迈向一个以自动驾驶为基础的未来。 擎天柱官推则更为明确地放出了这样一个视频，配文： Model S和X将通过我继续存在。 马斯克透露，在把特斯拉加州弗里蒙特工厂的Model S/X生产线改造成擎天柱生产线后，其机器人的产量将达到 每年一百万台 。 特斯拉「情怀」车型走向终结 Model S/X的退役，倒也不是无迹可寻。 毕竟马斯克2019年就说过，这两款分别诞生于2012年和2015年的车型纯粹是因为"情感原因"才被继续生产的。 数据很直接：在过去几年里，特斯拉每年能卖出差不多170万辆车，其中Model S/X也就占几个百分点，并且销量还在持续下降。 目的很明确，就是要给特斯拉机器人擎天柱 （Optimus） 让出生产线。 财报显示，特斯拉第四季度净利润为8.40亿美元，较上年同期下降了61%。 | ($ in million ...

马斯克旗下 脑机接口公司Neuralink周三表示，于正式开始人体测试两年后，公司目前在全球范围内的 临床试验中共有21名参与者，较去年9月的12人有所增加，当时该等参与者已经接受其芯片并用其通过 思维控制数位和实体工具。公司表示，正与监管机构和医院合作，为参与者提供改良的设备，并维持目 前未发生任何严重装置相关不良事件的纪录。 ...

我们不是资讯的搬运工 而是有态度的发现者 万和财富早班车 2026年1月29日 | 品种 | 收盘 | 涨跌幅 | 品种 | 收盘 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 上证指数 4151.24 | | 0.27% | 上证当月连续 | 3065.6 | -0.03% | | 深证成指 14342.89 | | 0.09% | 沪深当月连续 | 4727.8 | 0.08% | | 创业板指 | 3323.56 | -0.57% | 恒生期货指数 | 35848.43 | 2.66% | 宏观消息汇总 1.国家药监局: 《采用脑机接口技术的医疗器械范式设计与应 用规范运动功能重建》等2项医疗器械行业标准立项。 2国家能源局:截至2025年底,全国累计太阳能发电装机容量 12亿千瓦，同比增长35.4%。 3.国务院国资委：大力推进战略性、专业化重组和高质量并购。 2.盈新发展(000620)：拟5.2亿元收购长兴半导体60%股权，切入 存储芯片领域。 3.中牧股份(600195)：预计2025年度实现归属于上市公司股东的 净利润1.49亿元到1.92亿元 ...

马斯克发帖称，新一代神经链接 脑机接口增强版的性能将提升至三倍，将于今年晚些时候面市。待监 管部门批准后，Neuralink准备推出首款盲视增强技术，使那些完全失明的人能够以低分辨率视觉方式进 行感知。 ...

脑机接口技术作为生命科学与信息科学深度融合的交叉前沿技术，已成为全球科技竞争的新焦点。 2026年伊始，脑机接口"独角兽"浙江强脑科技有限公司宣布完成约20亿元的C轮融资。此次融资不仅创 下了脑机接口赛道除马斯克旗下Neuralink之外的全球第二大单笔融资纪录，也显示出资本对脑机接口产 业发展的强烈信心。 与此同时，从国家层面到地方政府，一系列涵盖产业培育、医疗服务定价等关键环节的利好政策相继出 台，为行业注入了强劲的推动力。产业、资本与政策同频共振，将脑机接口推至前所未有的热度。 在这幅火热的行业图景背后，一系列核心问题亟待厘清：中国脑机接口的真实发展水平究竟如何？与国 际前沿相比，我们的优势与差距何在？产业跃进的道路上，还有哪些核心瓶颈需要突破？带着这些问 题，记者走进"北脑一号"与"北脑二号"的诞生地——北京脑科学与类脑研究所(以下简称"北脑所")，与 北脑所所长、神经生物学家罗敏敏进行深入探讨。 追赶与超越 "在脑机接口领域，我国与其他国家在原理理论、技术积累、系统集成、临床应用等诸多方面还存在一 定差距。但是这种差距正在不断缩小。"罗敏敏对《证券日报》记者说，"过去几年，我国脑机接口技术 进展显著 ...